Literature DB >> 35875077

Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Jie Zhao1,2, Jinhui Guo3, Yanan Wang1, Qiancheng Ma1, Yu Shi1, Feng Cheng1, Qiliang Lu3, Wen Fu3, Guangxiong Ouyang3, Ji Zhang1, Qiuran Xu2, Xiaoge Hu4,5.   

Abstract

According to GLOBOCAN 2021 cancer incidence and mortality statistics compiled by the International Agency for Research on Cancer, hepatocellular carcinoma (HCC) is the most common malignancy in the human liver and one of the leading causes of cancer death worldwide. Although there have been great advances in the treatment of HCC, such as regofenib, sorafenib, and lomvatinib, which have been developed and approved for the clinical treatment of advanced or metastatic HCC. However, they only prolong survival by a few months, and patients with advanced liver cancer are susceptible to tumor invasion metastasis and drug resistance. Ubiquitination modification is a type of post-translational modification of proteins. It can affect the physiological activity of cells by regulating the localization, stability and activity of proteins, such as: gene transcription, DNA damage signaling and other pathways. The reversible process of ubiquitination is called de-ubiquitination: it is the process of re-releasing ubiquitinated substrates with the participation of de-ubiquitinases (DUBs) and other active substances. There is growing evidence that many dysregulations of DUBs are associated with tumorigenesis. Although dysregulation of deuquitinase function is often found in HCC and other cancers, The mechanisms of action of many DUBs in HCC have not been elucidated. In this review, we focused on several deubiquitinases (DUBs) associated with hepatocellular carcinoma, including their structure, function, and relationship to hepatocellular carcinoma. hepatocellular carcinoma was highlighted, as well as the latest research reports. Among them, we focus on the USP family and OTU family which are more studied in the HCC. In addition, we discussed the prospects and significance of targeting DUBs as a new strategy for the treatment of hepatocellular carcinoma. It also briefly summarizes the research progress of some DUB-related small molecule inhibitors and their clinical application significance as a treatment for HCC in the future.
Copyright © 2022 Zhao, Guo, Wang, Ma, Shi, Cheng, Lu, Fu, Ouyang, Zhang, Xu and Hu.

Entities:  

Keywords:  deubiquitinating enzymes; hepatocellular carcinoma; inhibitors; structure; targeted; ubiquitin

Year:  2022        PMID: 35875077      PMCID: PMC9303014          DOI: 10.3389/fonc.2022.920287

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   5.738


  207 in total

1.  The ubiquitin pathway in Parkinson's disease.

Authors:  E Leroy; R Boyer; G Auburger; B Leube; G Ulm; E Mezey; G Harta; M J Brownstein; S Jonnalagada; T Chernova; A Dehejia; C Lavedan; T Gasser; P J Steinbach; K D Wilkinson; M H Polymeropoulos
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

Review 2.  Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1.

Authors:  Xiao-Xin Sun; Mu-Shui Dai
Journal:  World J Biol Chem       Date:  2014-05-26

Review 3.  Sp1 transcription factor: A long-standing target in cancer chemotherapy.

Authors:  Carolina Vizcaíno; Sylvia Mansilla; José Portugal
Journal:  Pharmacol Ther       Date:  2015-05-08       Impact factor: 12.310

4.  Structural basis for the activation and inhibition of the UCH37 deubiquitylase.

Authors:  Ryan T Vander Linden; Casey W Hemmis; Benjamin Schmitt; Ada Ndoja; Frank G Whitby; Howard Robinson; Robert E Cohen; Tingting Yao; Christopher P Hill
Journal:  Mol Cell       Date:  2015-02-19       Impact factor: 17.970

5.  LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells.

Authors:  H Xiong; Z Ni; J He; S Jiang; X Li; J He; W Gong; L Zheng; S Chen; B Li; N Zhang; X Lyu; G Huang; B Chen; Y Zhang; F He
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

6.  The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.

Authors:  Nagalingam R Sundaresan; Vinodkumar B Pillai; Don Wolfgeher; Sadhana Samant; Prabhakaran Vasudevan; Vishwas Parekh; Hariharasundaram Raghuraman; John M Cunningham; Madhu Gupta; Mahesh P Gupta
Journal:  Sci Signal       Date:  2011-07-19       Impact factor: 8.192

7.  USP10 regulates p53 localization and stability by deubiquitinating p53.

Authors:  Jian Yuan; Kuntian Luo; Lizhi Zhang; John C Cheville; Zhenkun Lou
Journal:  Cell       Date:  2010-01-21       Impact factor: 41.582

Review 8.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

9.  Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde.

Authors:  Min Hu; Pingwei Li; Muyang Li; Wenyu Li; Tingting Yao; Jia-Wei Wu; Wei Gu; Robert E Cohen; Yigong Shi
Journal:  Cell       Date:  2002-12-27       Impact factor: 41.582

10.  USP16 Downregulation by Carboxyl-terminal Truncated HBx Promotes the Growth of Hepatocellular Carcinoma Cells.

Authors:  Yu Qian; Boshi Wang; Aihui Ma; Li Zhang; Guiqin Xu; Qi Ding; Tiantian Jing; Lin Wu; Yun Liu; Zhaojuan Yang; Yongzhong Liu
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.